What is HC Wainwright’s Forecast for ACTU FY2025 Earnings?

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Actuate Therapeutics in a research report issued on Tuesday, September 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.02) per share for the year, up from their previous forecast of ($1.05). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q1 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at $0.11 EPS.

Several other brokerages also recently issued reports on ACTU. B. Riley began coverage on shares of Actuate Therapeutics in a report on Tuesday, August 26th. They set a “buy” rating and a $20.00 price target for the company. Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Actuate Therapeutics presently has a consensus rating of “Buy” and an average price target of $20.33.

Actuate Therapeutics Trading Down 5.3%

Shares of NASDAQ:ACTU opened at $6.65 on Thursday. The company has a fifty day moving average of $7.53 and a 200-day moving average of $7.93. Actuate Therapeutics has a 52-week low of $5.47 and a 52-week high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Institutional Trading of Actuate Therapeutics

A number of institutional investors have recently bought and sold shares of ACTU. Voss Capital LP boosted its position in Actuate Therapeutics by 101.0% during the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock valued at $1,748,000 after acquiring an additional 143,759 shares during the last quarter. Geode Capital Management LLC boosted its position in Actuate Therapeutics by 252.5% during the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after acquiring an additional 84,561 shares during the last quarter. BIOS Capital Management LP boosted its position in Actuate Therapeutics by 0.7% during the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock valued at $60,887,000 after acquiring an additional 71,428 shares during the last quarter. Gleason Group Inc. bought a new stake in Actuate Therapeutics during the second quarter valued at $116,000. Finally, New York State Common Retirement Fund bought a new stake in Actuate Therapeutics during the second quarter valued at $105,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.